Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real‐world setting in China: Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization

BACKGROUND: To evaluate the 12-month efficacy and safety of intravitreal conbercept for myopic choroidal neovascularization (CNV). METHODS: A retrospective, observational study. Thirty-four eyes of 34 pathologic myopic patients with CNV were treated with intravitreal conbercept (IVC) 0.5 mg with a f...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Xin, Wang, Yulong, Yi, Hong, Qiao, Yanbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934258/
https://www.ncbi.nlm.nih.gov/pubmed/33663431
http://dx.doi.org/10.1186/s12886-021-01877-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934258/
https://www.ncbi.nlm.nih.gov/pubmed/33663431
http://dx.doi.org/10.1186/s12886-021-01877-8

Ejemplares similares